The BioHub - by Avetix

Welcome to The BioHub, where the doors to the world of biotechnology swing wide open. Join your host, Max Brennan, a seasoned biotech recruiter, as he engages in thought-provoking conversations with the brightest minds in biotech. This podcast is your backstage pass to the insights, strategies, and stories that fuel success in the dynamic and ever-evolving biotech landscape.Subscribe now and be part of the conversation that's shaping the future of biotechnology.Get ready for an immersive experience into the world of biotech with The BioHub.

The BioHub - by Avetix is a science podcast hosted by Max Brennan - Biotech HeadHunter, with 257 episodes on record and a Required Pod Score of 80.

Max Brennan - Biotech HeadHunter hosts The BioHub - by Avetix, a science show with 257 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  The BioHub - by Avetix

  Episode 237 - Marc Hedrick & Russell Bradley- Cerenome

  Oct 1, 202631 min

  In this episode of The BioHub Podcast, Ben is joined by Dr. Marc Hedrick, President & CEO of Cerenome, and Russell Bradley, President & General Manager of CNSide Diagnostics. We explore why CNS cancers remain so difficult to diagnose and treat, and how Cerenome is attempting to address both sides of that problem. Russell takes us inside CNSide®, the company’s cerebrospinal fluid-based diagnostic platform, including how it differs from traditional cytology, the importance of rare-cell characterisation, and what better diagnostic information could mean for treatment decisions. Marc then discusses REYOBIQ™, Cerenome’s targeted radiotherapeutic platform, the challenge of delivering sufficient therapeutic intensity into the CNS while managing toxicity, and the broader opportunity to connect diagnosis, treatment and longitudinal monitoring. A fascinating conversation at the intersection of diagnostics, therapeutics and precision CNS oncology.

  ListenShow Notes
• 

  Episode #236

  Episode 236 - Dan O’Connell - President & CEO of Acumen Pharmaceuticals

  Sep 28, 202629 minS2

  In this episode of The BioHub by Avetix , I’m joined by Dan O’Connell , President and CEO of Acumen Pharmaceuticals . Dan shares his journey from neuroscience investing and company creation into the CEO role, and how he has helped take Acumen from a private, preclinical biotech into a publicly traded clinical-stage company focused on Alzheimer’s disease. We discuss the origins of Acumen, what it was like taking the company public with just nine people, navigating a difficult few years for biotech, balancing financial discipline with clinical progress, and the major readout ahead later this year.

  ListenShow Notes
• 

  Episode #235

  Episode 235 - Paul Hastings - CEO NKarta

  Sep 25, 202642 minS2

  In this episode of The BioHub by Avetix , I’m joined by Paul Hastings , CEO of Nkarta . Paul has spent more than three decades in biotech, leading companies across oncology, rare disease and cell therapy, while also becoming one of the industry’s most prominent patient advocates. At Nkarta, he’s now leading the development of allogeneic NK cell therapies designed to make cell therapy safer, more scalable and more accessible. We discuss the evolution of biotech since Paul entered the industry in 1989, the future of cell therapy, the challenges of scaling access, the US clinical and regulatory environment, the importance of patient advocacy, and the mentors and lessons that have shaped his career.

  ListenShow Notes
• 

  The BioHub - by Avetix

  Epsiode 234 - Lei Fang CEO Excalipoint

  Sep 25, 202625 min

  We welcomed Lei Fang the CEO of Excalipoint to the BioHub

  ListenShow Notes
• 

  The BioHub - by Avetix

  Episode 233 - Jay Fine - President R&D at Evolveimmune Therapeutics

  Sep 24, 202636 min

  Today we’re joined by Jay Fine, President of Research & Development at EvolveImmune Therapeutics. Jay has spent more than 30 years working across drug discovery and development, with a career spanning immunology, immuno-oncology, inflammatory diseases and respiratory disorders. Before joining EvolveImmune, he spent many years at Boehringer Ingelheim, where he led global research efforts in immunology and respiratory diseases, with his teams playing a key role in advancing therapies including Skyrizi and Spevigo. Earlier in his career, Jay held leadership and research positions at Roche, Schering-Plough and the National Cancer Institute, giving him experience across academia, large pharma and biotech. Today, we’ll talk about Jay’s journey through the field, the lessons he’s learned from taking medicines from discovery into development, his experience building and leading scientific teams, and what he sees as the biggest opportunities and challenges in drug development today.

  ListenShow Notes

Recent guests on The BioHub - by Avetix. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.